In reply
- PMID: 25378542
- PMCID: PMC4221381
- DOI: 10.1634/theoncologist.2014-0332
In reply
Abstract
The authors respond to the observations and remarks of Cavanna et al. concerning the clinical guidance paper on giant cell tumor of bone (GCTB) in the era of denosumab and update the paper with respect to the European Medicines Agency’s recent positive opinion recommending denosumab for the treatment of adults and skeletally mature adolescents with GCTB that is unresectable or for which surgical resection is likely to result in severe morbidity
Comment on
-
The clinical approach toward giant cell tumor of bone.Oncologist. 2014 May;19(5):550-61. doi: 10.1634/theoncologist.2013-0432. Epub 2014 Apr 9. Oncologist. 2014. PMID: 24718514 Free PMC article. Review.
-
Giant cell tumor of bone.Oncologist. 2014 Nov;19(11):1207. doi: 10.1634/theoncologist.2014-0267. Oncologist. 2014. PMID: 25378541 Free PMC article.
References
-
- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2014. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2.... Accessed August 20, 2014.
-
- van der Bijl AE, Taminiau AH, Hermans J, et al. Accuracy of the Jamshidi trocar biopsy in the diagnosis of bone tumors. Clin Orthop Relat Res. 1997:233–243. - PubMed
-
- ESMO/European Sarcoma Network Working Group Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii100–vii109. - PubMed